Prima's Arthron signs deal with US based Xencor
09 September, 2005 by Helen SchullerArthron, a subsidiary of Prima Biomed (ASX:PRR) has signed a license and option agreement with US biotechnology company Xencor to utilise Arthron's Fc receptor technology for enhancing the effect of anti-cancer antibodies.
Proteome to raise $10 million
09 September, 2005 by Ruth BeranSydney proteomics R&D company Proteome Systems (ASX:PXL) will raise about $10 million through the issue of over 33 million fully paid ordinary shares to institutional and professional investors in the UK, US and Australia at a price of $0.30 per share.
Alchemia heartened by results from GSK drug
08 September, 2005 by Ruth BeranThe market potential for Brisbane biopharma Alchemia's (ASX:ACL) generic version of GlaxoSmithKline's (GSK) anti-blood clot drug Arixtra has been significantly enhanced by clinical trial results finding that the Arixtra is safer and as effective as Sanofi-Aventis' Lovenox, the traditional therapy used for preventing heart attacks, death and ischemia in people with serious heart conditions.
Why it's never too early for ethics
08 September, 2005 by Iain ScottIf your brain disengages when you read the word 'ethics', perhaps you'd better switch it on again, writes Iain Scott -- there's a lot you haven't heard on the subject.
Psivida to collaborate with US firm Cirrus
06 September, 2005 by Ruth BeranPerth nano-biotech company Psivida (ASX:PSD, NASDAQ:PSDV, Xetra:PSI) has contracted North Carolina-based R&D organisation Cirrus Pharmaceuticals to develop a number of specific drug candidates formulated in Psivida's modified silicon product BioSilicon.
Canola scare shows we're right: Chance
06 September, 2005 by Staff WritersWA agriculture minister Kim Chance has claimed that concerns over a canola crop which may have contained some genetically modified material have supported the state's moratorium on GM crops.
Second Sunshine implant removed after infection
05 September, 2005 by Helen SchullerThe second patient to receive Sunshine Heart's (ASX:SHC) C-Pulse device has had the device removed one month after it was implanted, after he developed a related infection.
Bone to become subsidiary of Bone Medical
05 September, 2005 by Ruth BeranPerth-based Bone Medical (ASX:BNE) has signed a share purchase agreement with UK R&D company Proxima Concepts to acquire 100 per cent control of British biopharma firm Bone -- the company that holds the licenses to Bone Medical's platform technologies.
Opara: biotech market needs education
05 September, 2005 by Ruth BeranDr Richard Opara, a substantial shareholder in biotech companies Polartechnics (ASX:PLT) and Avantogen (ASX:ACU), is trying to raise money for a new start-up capital biotech fund, but is finding the going tough in Australia and may have to go overseas to find the cash.
Clinical Cell Culture posts record revenues
02 September, 2005 by Ruth BeranTissue-engineering biomedical company Clinical Cell Culture (ASX:CCE, C3) has posted record revenues of AUD$1.4 million, up 51 per cent in the 18 month period from January 1, 2004 to June 30, 2005 (2003: $0.95 million).
Norwood raises US$10m from US investors
02 September, 2005 by Helen SchullerNorwood Abbey (ASX:NAL) has raised AUD$13.3 million (US$10 million) through US institutional investors to make the final payment on its products used in vision correction surgery and to expand production.
HeartWare implants first mini heart device
01 September, 2005 by Helen SchullerUS artificial heart firm HeartWare (ASX:HTW) has successfully commenced its animal studies by implanting its Miniaturised Ventricular Assist Device (MVAD) in a calf.
Pharmaxis boosted by cystic fibrosis study
31 August, 2005 by Helen SchullerPharmaxis' (ASX:PXS) drug Bronchitol has produced positive results from a phase II trial in cystic fibrosis patients, described by CEO Alan Robertson as "a landmark study and transforming day for Pharmaxis and the cystic fibrosis community".
Phylogica teams with Fox Chase
31 August, 2005 by Graeme O'NeillPhylogica (ASX:PYC) has signed a partnership with leading US cancer research institute, the Fox Chase Centre, that gives the Perth peptide therapeutics developer an exclusive global licence to exploit Fox Chase's proprietary technology to screen molecules for anti-cancer activity.
Antisense set to restart MS drug trial
31 August, 2005 by Helen SchullerMelbourne's Antisense Therapeutics (ASX:ANP) is planning to restart the phase IIa trial of its lead drug candidate for multiple sclerosis ATL1102 before the end of the year, following recommendations from its advisory board.
